Europe - Euronext Brussels - EBR:NYXH - BE0974358906 - Common Stock
The current stock price of NYXH.BR is 4.125 EUR. In the past month the price increased by 1.71%. In the past year, price decreased by -58.56%.
ChartMill assigns a technical rating of 1 / 10 to NYXH.BR. When comparing the yearly performance of all stocks, NYXH.BR is a bad performer in the overall market: 96.06% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to NYXH.BR. NYXH.BR may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NYXH.BR reported a non-GAAP Earnings per Share(EPS) of -2.24. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.29% | ||
| ROE | -164.01% | ||
| Debt/Equity | 0.4 |
14 analysts have analysed NYXH.BR and the average price target is 9.56 EUR. This implies a price increase of 131.82% is expected in the next year compared to the current price of 4.125.
For the next year, analysts expect an EPS growth of -22.33% and a revenue growth 48.25% for NYXH.BR
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
NYXOAH SA
Rue Edouard Belin 12
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 184
Phone: 3226121755
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
The current stock price of NYXH.BR is 4.125 EUR. The price decreased by -2.37% in the last trading session.
NYXH.BR does not pay a dividend.
NYXH.BR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
NYXOAH SA (NYXH.BR) currently has 184 employees.
NYXOAH SA (NYXH.BR) has a market capitalization of 177.50M EUR. This makes NYXH.BR a Micro Cap stock.